SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001714899-24-000111
Filing Date
2024-04-18
Accepted
2024-04-18 16:04:12
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2024fy23defa14aproxy-defi.htm DEFA14A 10368
2 denalitherapeuticsinc_proxb.jpg GRAPHIC 472841
3 denalitherapeuticsinc_proxc.jpg GRAPHIC 205096
  Complete submission text file 0001714899-24-000111.txt   944573
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38311 | Film No.: 24854305
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)